For AML patients with NPM1 mutation, it is currently known that combined application of all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) can degrade the mutant NPM1 protein and further induce the apoptosis of AML cells (7). Here, NPM1 is linked to acute myeloid leukemia.